anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemical-pharmaceutical industry. SUBSTANCE: method involves extraction of common immortelle (Helichrisum arenarium) inflorescences, extract evaporation, settling and filtration of an aqueous concentrate followed by treatment with a mixture of ethyl acetate and ethanol, separation of an organic phase from an aqueous one and its drying. Treatment of an aqueous concentrate with ethyl acetate with ethanol is carried out at countercurrent at stirring and at ratio = (1:2). An aqueous concentrate and ethyl acetate/ethanol mixture is fed at countercurrent at rates 47-53 l/h and 77-83 l/h at onset and 27-33 l/h and 42-48 l/h during the process, respectively. The prepared flamin is used for treatment cholecystitis and hepatitis. EFFECT: intensified process, increased yield of product, decreased reagent consumption. 7 tbl
The present disclosure addresses the problem of improving the accuracy of an infection risk evaluation. The infection risk evaluation system (1) comprises a position information acquisition unit (10), a sound information acquisition unit (11), an infected person information acquisition unit (12), a determination unit (13), a storage unit (14), and an evaluation unit (15). The position information acquisition unit (10) acquires position information for each of a plurality of subjects. The sound information acquisition unit (11) acquires sound information produced by each of the plurality of subjects. The infected person information acquisition unit (12) acquires infected person information for identifying a subject who is infected with an infectious disease. The determination unit (13) determines whether there has been close contact between the plurality of subjects at an arbitrary time and an arbitrary location on the basis of the position information. The storage unit (14) stores determination results from the determination unit (13) that indicate whether there has been close contact. The evaluation unit (15) evaluates the infection risk of each of the plurality of subjects on the basis of the determination results stored in the storage unit (14), the sound information, and the infected person information.
Grape juice has a high concentration of phenolic compounds and is capable of modulating biochemical parameters and oxidative stress. By naturally containing carbohydrates grape juice can help acutely minimize fatigue during exercise as well as long-term oxidative stress parameters in athletes. This project aims to evaluate if after 14 days of grape juice ingestion there is improvement of the parameters of strength, fatigue and oxidative stress in judo fighters. The study will be a randomized, blind, crossover clinical trial of 20 Judo athletes. Judo wrestling simulations will be performed on 3 different days. Each exercise session will consist of four 7-minute bouts, with 14-minute rest between them. The athletes will perform a first fight simulation without ingestion of any beverage (control group 1), and then will be randomized to determine the order of participation in the groups: maltodextrin (group 2 placebo) and grape juice (intervention group 3). Analyzes of oxidative stress; Muscle strength and fatigue; Perceived effort rate; Lactate; Heart rate; Analysis of food consumption and body composition.Two-way ANOVA will be used to evaluate the relation of the intervention and physical exercise, besides parameters of strength and fatigue. The level of significance adopted will be 5% and for the analysis, the SPSS summer 23 statistical program will be used.
Participants randomized to the Waitlist Control Group will receive nothing from the research group while the Intervention Group is underway. Participants will be asked to undergo an assessment collection point at baseline recruitment and 3-month completion time. After the Control Group's 3-month follow-up assessment, they will be offered the PLP+SDoH curriculum.
The present invention discloses a method of treating an individual or animal with diabetes and/or obesity. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor. Preferably, the preventative and therapeutic methods of the present invention involve administering - to a mammal in need thereof - a therapeutically effective amount of an inhibitor of a c-Src-family protein tyrosine kinase. The invention pertains to pharmaceutical compositions containing an inhibitor of a c-Src-family protein tyrosine kinase or an analog or metabolite thereof, or an inhibitor of another protein tyrosine kinase, and a pharmaceutically acceptable carrier. Purines and pyrimidines and other molecules useful in the treatment of diabetes and obesity are provided herein, in particular, pyrazolopyrimidines, cyanoquinolines, phenylaminopyrimidines, anilinoquinazolines and related compounds. The invention also provides cellular targets and assay compositions useful for the identification of additional novel therapeutic agents for the treatment of these disorders.
AIMS: The link between nocturia and cardiovascular disease (CVD) is frequently discussed in literature, yet the precise nature of this relationship remains poorly characterized. The existing literature was reviewed in order to address issues concerning the origin, diagnosis, management, and implications of the co-occurrence of CVD and nocturia.
METHODS: This review summarizes literature and recommendations regarding the link between CVD and nocturia discussed during a think-tank meeting held at the 2023 International Consultation on Incontinence-Research Society.
RESULTS: Cardiovascular disorders are often underestimated contributors to nocturia, with various potential mechanisms influencing nighttime urination, such as impact on fluid retention, atrial natriuretic peptide, and glomerular filtration rate. The redistribution of fluid from leg edema in supine position can lead nocturnal polyuria (NP). Additionally, sleep disturbances due to nocturia in itself may lead to CVD through an increase in blood pressure, insulin resistance, and inflammation. Disrupted circadian rhythms (e.g., in sleep pattern and urine production) were identified as critical factors in most etiologies of nocturia, and their contribution is deemed imperative in future research and treatment approaches, particularly in the aging population. NP can be detected through a simple bladder diary and can even be used to distinguish cardiac from noncardiac causes of nocturia. For the treatment of NP, desmopressin can be effective in select patients, however, caution and close monitoring is warranted for those with CVD due to increased risk of side effects.
CONCLUSIONS: Gaps were identified in the available evidence and clear cut recommendations were put forth for future research. It is essential to gain a deeper understanding of the mechanisms linking nocturia and CVD to develop optimal management strategies.
Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
The proposed study is a follow-up study to LCCC 1120 and 1413. The investigators have shown that de-intensification is efficacious in these two phase II studies. A major question is whether the investigators can de-intensify in patients with HPV-associated oropharyngeal cancer who have smoking histories. The investigators' hypothesis is that genomic profiling of patients' tumors (specifically for p53 mutations) will help in triaging patients to de-intensification versus standard of care. Patients with HPV-associated OPSCC will be enrolled regardless of smoking history and p53 mutational status will be assessed in patients with a smoking history. The investigators will use the same de-intensification chemoradiotherapy regimen already evaluated in LCCC 1120 and 1413 in patients with HPV-associated OPSCC who have a minimal smoking history and in patients with a smoking history but with wild-type p53. Patients with a smoking history who have mutated p53 will not receive de-intensified chemoradiotherapy, but instead will receive standard doses. The hypothesis is that by using genomics in the patients with a significant smoking history, the investigators will better select those who can be safely de-intensified. Circulating free HPV DNA (cf-HPV-DNA) will also be prospectively assessed from blood samples.
BACKGROUND: Polished baseplates were introduced into total knee arthroplasty (TKA) systems to reduce the incidence of backside wear. In 2004, a fixed-bearing knee arthroplasty system underwent a change in baseplate material from matt titanium to polished cobalt-chrome (CoCr) with the intention to reduce backside wear. Other design aspects were left unchanged. The aim of this study was to compare these implants with each baseplate using data from the Australian Orthopaedic Association National Joint Replacement Registry.
METHODS: Primary TKA procedures performed between January 2010 and December 2021 for osteoarthritis, using a single design with cross-linked polyethylene inserts and matt titanium or polished CoCr baseplates, were analyzed. The primary outcome was all-cause revision, summarized using Kaplan-Meier estimates, with age- and sex-adjusted hazard ratios estimated from Cox proportional hazards models. In total, there were 2,091 procedures with matt titanium and 2,519 procedures with polished CoCr baseplates.
RESULTS: The 9-year cumulative percent revision was 2.5% (95% confidence interval [CI] 1.8 to 3.5%) and 4.2% (95% CI 3.1 to 5.6%) for the matt titanium and CoCr groups, respectively. Compared to matt titanium, the revision rate of CoCr baseplates was not significantly higher (hazard ratio 1.44; 95% CI 0.96 to 2.15; P = .076).
CONCLUSIONS: Polished CoCr baseplates in a single TKA system were not associated with reduced all-cause revision rates compared to matt titanium up to 11 years post-TKA. Our results suggest that the predicted reduction in wear particle debris production from polished CoCr baseplates may not correlate with reduced revision rates in vivo, but further evaluation is required.
Chagasic chronic cardiomyopathy (CCC) is the primary clinical manifestation of Chagas disease (CD), caused by Trypanosoma cruzi. Current therapeutic options for CD are limited to benznidazole (Bz) and nifurtimox. Amiodarone (AMD) has emerged as most effective drug for treating the arrhythmic form of CCC. To address the effects of Bz and AMD we used a preclinical model of CCC. Female C57BL/6 mice were infected with T. cruzi and subjected to oral treatment for 30 consecutive days, either as monotherapy or in combination. AMD in monotherapy decreased the prolonged QTc interval, the incidence of atrioventricular conduction disorders and cardiac hypertrophy. However, AMD monotherapy did not impact parasitemia, parasite load, TNF concentration and production of reactive oxygen species (ROS) in cardiac tissue. Alike Bz therapy, the combination of Bz and AMD (Bz/AMD), improved cardiac electric abnormalities detected T. cruzi-infected mice such as decrease in heart rates, enlargement of PR and QTc intervals and increased incidence of atrioventricular block and sinus arrhythmia. Further, Bz/AMD therapy ameliorated the ventricular function and reduced parasite burden in the cardiac tissue and parasitemia to a degree comparable to Bz monotherapy. Importantly, Bz/AMD treatment efficiently reduced TNF concentration in the cardiac tissue and plasma and had beneficial effects on immunological abnormalities. Moreover, in the cardiac tissue Bz/AMD therapy reduced fibronectin and collagen deposition, mitochondrial damage and production of ROS, and improved sarcomeric and gap junction integrity. Our study underlines the potential of the Bz/AMD therapy, as we have shown that combination increased efficacy in the treatment of CCC.
FIELD: biochemical technology. SUBSTANCE: lipid starting material is dissolved in an organic solvent. The resulting solution is dispersed with aqueous solution containing low- molecular weight compounds in the presence of 5-10 % of a cryoprotectant. The resulting aqueous suspension is lyophilized, rehydrated to the initial volume, and the compounds that fail to be included into the lyposomes are removed by the dialysis method. EFFECT: increased inclusion of low-molecular compounds to liposomes. 1 cl, 5 tbl
NEW MATERIAL:A cell growth inhibiting substance WAS-Z414101 extracted from body hair of mammals. Molecular formula; C10H12N2O3. Melting point; 195-200 deg.C (decomposition). Solubility; Readily soluble in water, soluble in acetonitrile and DMSO and insoluble in ethyl alcohol, ether, etc. USE:An anticancer agent and immunosuppressive agent having remarkable growth inhibitory action on cancerous cells, e.g. cells derived from mouse lymphatic cell ascitic tumor and useful as a treating agent, preventing agent for malignant tumor, leukemia, etc., and rejection inhibitor after transplating of internal organs, etc. PREPARATION:The body hair of mammals, e.g. rat, mouse, sheep, etc., is extracted with water to give a water-soluble fraction, which Various fractionating and purifying means such as dialysis, gel filtration, ion exchange method, reversed phase chromatography, etc., based on the above-mentioned physico-chemical properties are suitably used to isolate and prepare WAS-Z414101.
Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
PURPOSE: A pharmaceutical composition containing Perilla frutescens extract or Japanese apricot is provided to reduce immunocyte number and suppress dermatitis without side effect. CONSTITUTION: A pharmaceutical composition for preventing and/or treating dermatitis contains 0.1-3 wt% of Perilla frutescens extract and 0.1-3 wt% of Japanese apricot extract. The extract is isolates using water or alcohol. The water extract is prepared by boiling a mixture of water and Perilla frutescens or Japanese apricot with water for 3-8 hours, removing precipitate, and freeze-drying. The alcohol extract is prepared by reflux extraction of the mixture and alcohol for 30 minutes to 5 hours, removing precipitate, and freeze-drying. The dermatitis includes contact dermatitis or atopic dermatitis.
Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.
Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is unknown. Novel tumor-specific antigens (TSAs) shared by a large proportion of ovarian tumors are described herein. Most of the TSAs (>80%) described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also described.
Ultrasonography guidance, by virtue of real-time visualization of the muscle layers and fascial planes, has significantly facilitated practice of regional nerve blockade for it offers confirmation of the spread of the local anesthetic drug in the correct space. Interestingly, there has been a reinvigoration of interest in ultrasonography-guided transversus abdominis plane block in children since its emergence as a valid postoperative analgesia alternative in adults undergoing abdominal surgery. transversus abdominis plane block involves blockade of spinal afferent nerves in the neurofascial plane between the internal oblique and transversus abdominis muscle. Whereas the advantages (reduction in pain intensity/analgesic requirements) of ultrasonography-guided transversus abdominis plane block have been well documented in adults in the first 48 hours post surgery, in children, its use as a primary postoperative analgesia technique remains limited. Caudal anesthesia is easy to perform in younger children; however, its main disadvantage is the short duration of action. Even bupivacaine, along-acting local anesthetic drug, can provide only4-8 h of analgesia. Dexmedetomidine is a highly selective alfa2 agonist with sedative and analgesic properties. It has an alfa1/2 selectivity ratio of 1600 : 1, which is eight times more potent than clonidine (200 : 1)\[16\]. DEX has been used effectively in intensive care to aid weaning from mechanical ventilation and is being used increasingly in children
Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
Participants will be randomly assigned to XR-BUP, with approximately 96 in the XR-BUP condition. The XR-BUP condition will use Brixadi/CAM2038 injectable, extended-release buprenorphine (Braeburn Pharmaceuticals, Inc.). After titrating to a stable dosage in approximately two weeks using weekly injection dosages as clinically indicated to relieve cravings and withdrawal symptoms, the target monthly dosage (128mg) of XR-BUP will be administered by injection at approximately Day 14 and approximately four weeks later in Week 6, with a third injection in Week 10. Dosage adjustments will be made as indicated for tolerability.
DSUVIA contains sufentanil, a substance with a high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions (5.3)].

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of DSUVIA increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of DSUVIA with alcohol and/or other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of DSUVIA abuse include those with a history of prolonged use of any opioid, including products containing sufentanil, those with a history of drug or alcohol abuse, or those who use DSUVIA in combination with other abused drugs.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

DSUVIA, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
The invention relates to a traditional Chinese medicine achyranthes root-rhizoma curculiginis wine for treating impotence. The traditional Chinese medicine achyranthes root-rhizoma curculiginis wine is mainly used for solving the problem that the current drugs for treating impotence are poor in treatment effect and have side effects. The traditional Chinese medicine achyranthes root-rhizoma curculiginis wine is prepared through the steps of preparing 100g of epimedium, 100g of rhizoma curculiginis, 100g of medlar, 50g of achyranthes root, 3 centipedes and 1,000ml of liquor, soaking the medicines into the wine, and sealing for half a month while shaking once every day. The usage and dosage are as follows: the wine is orally taken by 24ml once in the morning and evening of a day with an empty stomach. The traditional Chinese medicine achyranthes root-rhizoma curculiginis wine has the aims and advantages that the total effective rate for impotence treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine achyranthes root-rhizoma curculiginis wine is free from toxic and side effects.
PROBLEM TO BE SOLVED: To obtain a new serine protease derived from a human colonic cancer cell and available from genetic engineering, having a specific amino acid sequence capable of establishing a screening system of an inhibitor specific to the enzyme and utilizing for screening, etc., of treating agents for various kinds of diseases. SOLUTION: This new serine protease or its partially peptide contains an amino acid sequence (leucine of amino acid No. 1 may be lost) of amino acid Nos. 1-223 represented by formula 1, an amino acid sequence of an amino acid Nos. 1-233 represented by formula II and an amino acid sequence of amino acid Nos. 1-241 represented by formula III, and can be utilized for screening, etc., of a treating agent for various kinds of diseases by screening system of an inhibitor which is specific to the enzyme. The serine protease is obtained by extracting mRNA from COLO 201 cell derived from human colonic cancer and preparing cDNA library using the mRNA and screening cDNA library, integrating the resultant serine protease gene into a vector and expressing the gene in a host cell.